Physician profile
James E Young
NPI 1871536268
$2,223.35
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $340 · 2020: $485 · 2021: $788 · 2022: $394 · 2023: $216.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $216.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $216.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $718.13 | 2019-2022 | |
| Novo Nordisk INC | $580.51 | 2019-2023 | Rybelsus, Ozempic |
| Glaxosmithkline, LLC. | $185.55 | 2020-2023 | Trelegy Ellipta, Shingrix |
| Pfizer INC. | $111.40 | 2020-2023 | |
| Janssen Pharmaceuticals, INC | $108.37 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $91.40 | 2019 | |
| Allergan, INC. | $80.64 | 2019 | |
| Lilly USA, LLC | $79.28 | 2020-2023 | Mounjaro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $75.51 | 2021-2023 | Jardiance |
| Takeda Pharmaceuticals U.S.A., INC. | $74.46 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $63.00 | 2020-2021 | |
| E.R. Squibb & Sons, L.L.C. | $15.66 | 2022 | |
| Boston Scientific Corporation | $14.11 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $13.86 | 2021 | |
| Amgen INC. | $11.47 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Young listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.